Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome

Clinical Cancer Research

Volumn 21, Issue 22, 2015, Pages 5164-5172

  Calió, Anna ^a   Zamó, Alberto ^a   Ponzoni, Maurilio ^b   Zanolin, Maria Elisabetta ^a   Ferreri, Andrés J M ^c   Pedron, Serena ^a   Montagna, Licia ^a   Parolini, Claudia ^a   Fraifeld, Vadim E ^d   Wolfson, Marina ^d   Yanai, Hagai ^d   Pizzolo, Giovanni ^e   Doglioni, Claudio ^b   Vinante, Fabrizio ^e   Chilosi, Marco ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 1A; TUMOR MARKER;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENESCENCE; BIOSYNTHESIS; CELL AGING; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL AGING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 84954150815     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0508     Document Type: Article

References (49)

1. Derenzini E, Younes A. Predicting treatment outcome in classical Hodgkin lymphoma: Genomic advances. Genome Med 2011;3:26.
2. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 2004;5:19-26.
3. Zanotti R, Trolese A, Ambrosetti A, Nadali G, Visco C, Ricetti MM, et al. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol 2002;13:1908-14.
4. Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998;91:3011-6.
5. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467-73.
6. Diepstra A, van ImhoffGW, Karim-Kos HE, van den Berg A, te Meerman GJ, NiensM, et al.HLAclass II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007;25:3101-8.
7. SteidlC,Diepstra A, Lee T, Chan FC, Farinha P, Tan K, et al. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood 2012;120: 3530-40.
8. Hummel M, Ziemann K, Lammert H, Pileri S, Sabattini E, Stein H. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N Engl J Med 1995;333:901-6.
9. Chilosi M, Pizzolo G. Biopathologic features of Hodgkin's disease. Leuk Lymphoma 1995;16:385-95.
10. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9:15-27.
11. Doglioni C, Pelosio P, Mombello A, Scarpa A, Chilosi M. Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30 anaplastic lymphomas. Hematol Pathol 1991;5:67-73.
12. Chilosi M, Doglioni C, Magalini A, Inghirami G, Krampera M, Nadali G, et al. p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: A potential marker of p53 tumor-suppressor gene function. Blood 1996;88:4012-20.
13. Guenova M, Rassidakis GZ, Gorgoulis VG, Angelopoulou MK, Siakantaris MR, Kanavaros P, et al. p16INK4A is regularly expressed in Hodgkin's disease: Comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr virus. Mod Pathol 1999;12:1062-71.
14. Kim LH, Peh SC, Poppema S. Expression of retinoblastoma protein and P16 proteins in classic Hodgkin lymphoma: Relationship with expression of p53 and presence of Epstein-Barr virus in the regulation of cell growth and death. Hum Pathol 2006;37:92-100.
15. Ju Z, Choudhury AR, Rudolph KL. A dual role of p21 in stem cell aging. Ann N Y Acad Sci 2007;1100:333-44.
16. Campisi J. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 2005;120:513-22.
17. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009;11:973-9.
18. Fumagalli M, d'Adda di Fagagna F. SASPense and DDRama in cancer and ageing. Nat Cell Biol 2009;11:921-3.
19. Salminen A, Kauppinen A, Kaarniranta K. Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal 2012;24:835-45.
20. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62:1876-83.
21. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003;63:2705-15.
22. Tacutu R, Budovsky A, Yanai H, Fraifeld VE. Molecular links between cellular senescence, longevity and age-related diseases-a systems biology perspective. Aging 2011;3:1178-91.
23. Swerdlow SH, Campo E, Harris NL, Vardiman JW, editors. WHO classification of tumour of haematopoietic and lymphoid tissue. 2008.
24. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
25. Hoppe RT. Radiation therapy in the management of Hodgkin's disease. Semin Oncol 1990;17:704-15.
26. Longo DL. The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol 1990;17:716-35.
27. Geissinger E, Sadler P, Roth S, Grieb T, Puppe B, Muller N, et al. Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30 T-cell lymphoproliferations. Haematologica 2010; 95:1697-704.
28. Vazquez M, Nogales-Cadenas R, Arroyo J, Botias P, Garcia R, Carazo JM, et al. MARQ: An online tool to mine GEO for experiments with similar or opposite gene expression signatures. Nucleic Acids Res 2010;38:W228-32.
29. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res 2013;41:D991-5.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
31. Cox DR. Regression models and life-tables. J Royal Stat Soc Series B (Methodological) 1972;34:187-220.
32. Vinante F, Rigo A, Tecchio C, Morosato L, Nadali G, RicettiMM, et al. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: Correlationwith clinical and biological features and outcome. Br J Haematol 1998;102:1025-34.
33. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
34. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006;6:472-6.
35. Coppe JP, Rodier F, Patil CK, Freund A, Desprez PY, Campisi J. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem 2011;286:36396-403.
36. McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclindependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998;8:351-4.
37. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004;23:2919-33.
38. Chilosi M, Doglioni C,Menestrina F, Montagna L, Rigo A, LestaniM, et al. Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood 1994;84:4295-300.
39. Knecht H, Sawan B, Lichtensztejn D, Lemieux B, Wellinger RJ, Mai S. The3D nuclear organization of telomeres marks the transition from Hodgkin to Reed-Sternberg cells. Leukemia 2009;23:565-73.
40. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell-cycle arrest of human naevi. Nature 2005;436:720-4.
41. Chilosi M, Facchetti F, Cali-o A, Zam-o A, Brunelli M, Martignoni G, et al. Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis. Leuk Lymphoma 2014;55:2620-6.
42. Martinelli P, Bonetti P, Sironi C, Pruneri G, Fumagalli C, Raviele PR, et al. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood 2011; 117:6617-26.
43. Visco C, Canal F, Parolini C, Andreoli A, Ambrosetti A, Krampera M, et al. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma. Haematologica 2006;91:687-90.
44. Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: Analyses using tissue microarrays. Blood 2003;101:681-9.
45. Garcia JF, Villuendas R, Algara P, Saez AI, Sanchez-Verde L, Martinez-Montero JC, et al. Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. Lab Invest 1999;79:1453-9.
46. ColladoM, Blasco MA, SerranoM. Cellular senescence in cancer and aging. Cell 2007;130:223-33.
47. Skalska L, White RE, Parker GA, Turro E, Sinclair AJ, Paschos K, et al. Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog 2013;9:e1003187.
48. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: From latent genes to tumours. Oncogene 2003;22:5108-21.
49. Yang X, He Z, Xin B, Cao L. LMP1 of Epstein-Barr virus suppresses cellular senescence associated with the inhibition of p16INK4a expression. Oncogene 2000;19:2002-13.